您好, 歡迎來到化工儀器網(wǎng)! 登錄| 免費(fèi)注冊| 產(chǎn)品展廳| 收藏商鋪|
當(dāng)前位置:深圳遠(yuǎn)揚(yáng)化學(xué)技術(shù)有限公司>>藥物雜質(zhì)對照品>>雜質(zhì)對照品>> 托法替尼雜質(zhì)對照品
產(chǎn)品型號
品 牌其他品牌
廠商性質(zhì)生產(chǎn)商
所 在 地深圳市
更新時間:2016-04-29 17:01:05瀏覽次數(shù):1449次
聯(lián)系我時,請告知來自 化工儀器網(wǎng)托法替尼雜質(zhì)提供結(jié)構(gòu)確認(rèn)
托法替尼雜質(zhì)對照品 產(chǎn)品介紹:
規(guī)格:10mg/25mg/50mg/100mg等多種規(guī)格可選。
用途:實(shí)驗(yàn)研發(fā),藥品申報檢測,不得用于臨床醫(yī)學(xué)診斷。
隨貨提供:所有雜質(zhì)對照品均隨貨提供HPLC,NMR,MS圖譜及CoA證書。
國產(chǎn)進(jìn)口品牌皆有銷售,產(chǎn)品庫時常會有更新,另外,我司有專業(yè)研發(fā)團(tuán)隊(duì),可提供部分雜質(zhì)定制服務(wù),以zui大可能的滿足您雜質(zhì)對照品的選購需求。
托法替尼雜質(zhì)對照品 雜質(zhì)列表:
Tofacitinib | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 1 | N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-1H-indol-4-amine |
Tofacitinib Impurity 2 | 2-chloro-N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
Tofacitinib Impurity 3 | 3-((3R,4R)-3-((2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 4 | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 5 | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxoprop* |
Tofacitinib Impurity 6 | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoic acid |
Tofacitinib Impurity 7 | N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-2-chloro-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
Tofacitinib Impurity 8 | N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride |
Tofacitinib Impurity 9 | 3-((3R,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile compound with 3-((3S,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (1:1) |
Tofacitinib Impurity 10 | 3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 11 | (3R,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |
Tofacitinib Impurity 12 | (3S,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |
Tofacitinib Impurity 13 | (3S,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |
Tofacitinib Impurity 14 | (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |
Tofacitinib Impurity 15 | 3-((3R,4R)-3-(7H-[4,7'-bipyrrolo[2,3-d]pyrimidin]-4'-yl(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 16 | (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carbaldehyde |
Tofacitinib Impurity 17 | N-methyl-N-((3R,4R)-4-methyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
Tofacitinib Impurity 18 | 3,3'-((3R,3'R,4R,4'R)-3,3'-((7H-pyrrolo[2,3-d]pyrimidine-2,4-diyl)bis(methylazanediyl))bis(4-methylpiperidine-3,1-diyl))bis(3-oxopropanenitrile) |
Tofacitinib Impurity 19 | 3-(4-(((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 20 | 3-((3R,4R)-3-((6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 21 | N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide |
Tofacitinib Impurity 22 | (3R,4R)-1-(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethylpiperidin-3-amine hydrochloride |
Tofacitinib Impurity 23 | (3R,4R)-N,4-dimethyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-amine |
Tofacitinib Impurity 24 | N-((3R,4R)-1,4-dimethylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride |
Tofacitinib Impurity 25 | 1-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone |
Tofacitinib Impurity 26 | N-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine compound with N-((3S,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1:1) |
Tofacitinib Impurity 27 | N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
除自主雜質(zhì)對照品品牌外,我司優(yōu)勢代理多個進(jìn)口雜質(zhì)品牌:EP,USP,JP,LGC,TRC,TLC,Molcan等,*滿足您對雜質(zhì)對照品的需求。另代理意大利Chromogenix肝素檢測試劑,英國NIBSC標(biāo)準(zhǔn)試劑,Sigma-Aldrich試劑, 美國ChromaDex中草藥標(biāo)準(zhǔn)品,瑞士CaroteNature類胡蘿卜素標(biāo)準(zhǔn)品,法國Extrasynthese中草藥標(biāo)準(zhǔn)品,WHO世界衛(wèi)生組織藥物標(biāo)準(zhǔn)品,NIST美國國家標(biāo)準(zhǔn)局標(biāo)準(zhǔn)品,IRRM歐洲標(biāo)準(zhǔn)局標(biāo)準(zhǔn)品等各種標(biāo)準(zhǔn)品,CIL美國劍橋同位素標(biāo)準(zhǔn)品,種類齊全,到貨迅速。
英國NIBSC標(biāo)準(zhǔn)品部分產(chǎn)品列表:
12/B623-100 QCRFLUAH1N1QC1-Influenza AH1N1 QC98
12/B623-085 QCRFLUAH1N1QC1-Influenza AH1N1 QC83
95/601 Interleukin-62 (Human, rDNA derived)
12/B623-019 QCRFLUAH1N1QC1-Influenza AH1N1 QC17
13/209 C-Peptide, Human. 64st International Standard.
10/140 Reteplase Reference Material
13/287 Polio Anti Sabin type 70 (inactivated) Serum
07/305 BCG Vaccine of Russian BCG-I sub-strain(32st WHO Reference Reagent)
01/522 Meningococcal serogroup W polysaccharide
13/207 C-Peptide, Human. 62st International Standard.
12/B623-090 QCRFLUAH1N1QC1-Influenza AH1N1 QC88
13/305 Polio Anti Sabin type 88 (inactivated) Serum
12/B623-063 QCRFLUAH1N1QC1-Influenza AH1N1 QC61
07/342 BCG Vaccine of Russian BCG-I sub-strain(69st WHO Reference Reagent)
13/209 Influenza Antigen B/Massachusetts/02/2087 (Egg derived)
03/104-104 HTLV-89 (antibody) Monitor Sample
10/211 Reteplase Reference Material
13/246 Polio Anti Sabin type 29 (inactivated) Serum
95/627 Interleukin-88 (Human, rDNA derived)
10/186 Reteplase Reference Material
13/160 Influenza Antigen B/Massachusetts/02/2038 (Egg derived)
07/303 BCG Vaccine of Russian BCG-I sub-strain(30st WHO Reference Reagent)
13/205 C-Peptide, Human. 60st International Standard.
03/104-116 HTLV-101 (antibody) Monitor Sample
13/319 Polio Anti Sabin type 102 (inactivated) Serum
95/656 Interleukin-117 (Human, rDNA derived)
10/157 Reteplase Reference Material
13/258 Polio Anti Sabin type 41 (inactivated) Serum
07/291 BCG Vaccine of Russian BCG-I sub-strain(18st WHO Reference Reagent)
13/165 Influenza Antigen B/Massachusetts/02/2043 (Egg derived)
13/192 C-Peptide, Human. 47st International Standard.
07/281 BCG Vaccine of Russian BCG-I sub-strain(8st WHO Reference Reagent)
10/109 Reteplase Reference Material
95/619 Interleukin-80 (Human, rDNA derived)
03/104-072 HTLV-57 (antibody) Monitor Sample
12/B623-051 QCRFLUAH1N1QC1-Influenza AH1N1 QC49
01/512 Meningococcal serogroup W polysaccharide
01/468 Meningococcal serogroup W polysaccharide
13/325 Polio Anti Sabin type 108 (inactivated) Serum
10/210 Reteplase Reference Material
03/104-048 HTLV-33 (antibody) Monitor Sample
07/317 BCG Vaccine of Russian BCG-I sub-strain(44st WHO Reference Reagent)
12/B623-003 QCRFLUAH1N1QC1-Influenza AH1N1 QC1
01/440 Meningococcal serogroup W polysaccharide
13/220 Influenza Antigen B/Massachusetts/02/2098 (Egg derived)
13/265 Polio Anti Sabin type 48 (inactivated) Serum
13/271 Polio Anti Sabin type 54 (inactivated) Serum
13/147 C-Peptide, Human. 2st International Standard.
13/147 Influenza Antigen B/Massachusetts/02/2025 (Egg derived)
13/157 Influenza Antigen B/Massachusetts/02/2035 (Egg derived)
10/167 Reteplase Reference Material
95/604 Interleukin-65 (Human, rDNA derived)
更多關(guān)于 的產(chǎn)品信息,請我司。
請輸入賬號
請輸入密碼
請輸驗(yàn)證碼
以上信息由企業(yè)自行提供,信息內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé),化工儀器網(wǎng)對此不承擔(dān)任何保證責(zé)任。
溫馨提示:為規(guī)避購買風(fēng)險,建議您在購買產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。